It is no consolation to the
roughly one out of 600 families who lost their homes in the U.S. but Wall Street made a lot of money slicing and dicing mortgages it knew would implode, while hiding risks. Financial giants, like AIG, are still
buzzing along and neither penalties or new laws will prevent a future crash, say financial analysts, because the risky business models have not really changed.A similar Big Pharma bubble, leavened with risky blockbuster drugs that also blew up, is now bursting. Like Wall Street’s bundled high risk loans, the “tide” created by Big Pharma’s high risk drugs raised many ships during the 2000s from advertising, public relations and medical communication agencies to TV and radio stations, medical journals and doctor/pitchmen who shoveled in its marketing budgets. But now the joy ride is over and Pharma is shedding jobs and settling billions in claims without changing its risky business model, like Wall Street.
In Europe, governments are no longer willing to pay the high prices for drugs that they once did say
published reports
and some countries are drafting laws making drug makers “prove their drugs are effective or risk having them dropped from the coverage list, or covered at a lower rate.” Imagine!
Germany has already saved 1.9 billion euros in 2011 by refusing to pay higher prices for drugs unless they are clearly superior to existing medicines, and Pharma worries that other countries will also get tough and want scientific proof for drug effectiveness instead of marketing and spin. In the U.S. and elsewhere, a drug only needs to be superior to no drug (placebo) to be approved by regulators — yet “new” is conveyed as “better than any drug to date” in advertising. Some clinicians say Haldol, an inexpensive antipsychotic, and lithium, a similar affordable bipolar drug are
better than blockbuster antipyschotics and bipolar drugs that created Pharma’s 2000 bubble.Before the
Vioxx scandal and major settlements over blockbuster drugs like
Zyprexa,
Bextra, Celebrex, Geodon and
Seroquel, being a Pharma rep was probably the next best thing to working on Wall Street. Direct-to-consumer advertising did your pre-sell for you, and all you had to do was show up with your snappy Vytorin tote bag and samples case. Some Pharma reps had their own reception room with ice water, swivel chairs, and laptop ports at medical offices, and most waltzed in to see the doctor right in front of waiting and sick patients. (It didn’t hurt that reps were usually “hotties,” both men or women).
But, by 2011, the bloom had fallen off Pharma reps’ roses. The number of prescribers willing to see most reps fell almost 20 percent, the number refusing to see all reps increased by half, and eight million sales calls were “nearly impossible to complete,” reported
ZS Associates. Blockbuster drugs that were found to be unsafe after their big sales push or even withdrawn altogether, did not help the reps’ credibility with doctors. After the aggressively marketed hormone therapy was linked to high incidences of cancer, stroke and heart attack, Wyeth (now Pfizer)
announced it was eliminating 1,200 jobs and closing its Rouses Point, New York plant where Prempro products were manufactured.
As government and private insurers increasingly say, “You want us to cover what?” about expensive, dangerous drugs that are not even proven effective, Pharma bubble jobs are evaporating. Almost 20,000 jobs have vanished at
AstraZeneca,
Novartis and Pfizer in the last 12 months alone. (AstraZeneca scrapped 21,600 more since 2007). Meanwhile, Pharma is outsourcing more of its operations to poor countries.
Workers and people willing to be trial subjects are both a bargain in poor countries where many can’t understand drug risks or refuse them if they did (and most can’t afford the very drugs they help sell). In January the Argentinian Federation of Health Professionals
accused drug maker GlaxoSmithKline of misleading participants and pressuring poor families into joining a trial for the Synflorix vaccine, which the company says protects against bacterial pneumonia and meningitis, reported CNN. In 2010,
10 deaths occurred during Pfizer and AstraZeneca drug trials at the Bhopal Memorial Hospital and Research Centre which was ironically built for survivors of the 1984 Bhopal gas disaster, reports MSNBC. 3,878 workers perished in Bhopal when chemicals leaked at a
Union Carbide pesticide plant.
Outsourcing drug manufacturing to cheap venues also contributes to Pharma’s cascade of “quality control” problems in which drugs are mislabeled, contaminated or otherwise made dangerous. It is speculated that Johnson & Johnson’s CEO William Weldon “was pushed to retire because of all of the quality issues at McNeil as well as with the company’s hip implant products, which have resulted in a raft of litigation,” reports
FiercePharma.
Like the Wall Street bubble, the Pharma bubble was built on products that industry, but not the public, knew were risky, sold for quick profits. Now regulators are examining some of these “assets” more closely and with disturbing findings. The
FDA now warns that bestselling statin drugs like Lipitor and Crestor, even approved for
children, are linked to memory loss and diabetes associated with. The equally well selling proton pump inhibitors like Nexium and Prilosec for acid reflux disease (GERD) are now believed to increase the risk of
bone fractures by 30 percent.
In March, the FDA even rejected a Merck drug that combines the active drug in Lipitor with the active drug in Zetia and Vytorin, a drug that
Forbes
calls Son of Vytorin. Vytorin (the father) was advertised to treat both food and family “sources of cholesterol” until results from a study that Merck and Schering-Plough appeared to withhold from regulators showed the drug had no effect on the buildup of plaque in the arteries (believed to correlate with heart attack and stroke). There was such a gap between marketing and science, Sen. Chuck Grassley (R-Iowa)
asked the General Accounting Office to investigate why the FDA was approving “drugs that appear to have little to no effect in protecting lives and increasing health.”
Yet even as clouds develop over Pharma’s top-selling drugs, some say the FDA is too hard on new drugs, not too easy. “
The FDA is impeding useful innovations in the U.S.,” says former FDA deputy commissioner Scott Gottlieb in the a
Wall Street Journal
oped and lagging behind other countries. Former FDA commissioner Andrew Von Eschenbach, also writing in the WSJ, agrees. The FDA should improve U.S. drug competitiveness by
allowing drugs “to be approved based on safety, with efficacy to be proven in later trials,” while the public is already taking the drugs. Isn’t that what’s happening now?
Biotecnika Info Labs Pvt Ltd, Bangalore is a Parent Company which runs India’s Largest Biosciences Career & education Portal. Biotecnika is where in technology meets life sciences.
“We are a fast growing Bio-techno-media company with extremely talented and fun Loving people you would love to work with. Biotecnika is run by a group of Doctorate & post Doctorates of lifesciences & together we help in the upliftment of postgraduates from any lifesciences background. If you do not like processes, hate pyramid type organizations; love creativity, innovation and fun at work; you will love it here. You will find a very flexible work environment, which treats people like human beings”
- Post: Business Development Executive
- Company Name: Biotecnika Info Labs Pvt Ltd
- Location: in Bengaluru/Bangalore
- Experience: 0 to 3 yrs
- Salary: INR 1,75,000 - 2,50,000 P.A
- Opening(s): 5
Qualification & Duties
- Must be a MSc graduate in Bioscience
- 0 - 3 years Sales experience.
- MBA preferred
- Good written and oral communication
- Client follow ups
- Candidate should be willing to sell services and product.
- Candidates have to generate leads, qualify the leads on the sales strategies, identify the potential client, client interaction and maintain client relationship.
- Understanding the requirement of client and offering them with the appropriate services and product.
- Follow up with clients.
- Ability to meet multiple objectives within an organization.
- Work on Online marketing, Social Media Marketing, Email marketing, Tele Marketing as well as Field marketing
- Selling should be your signature statement.
- Maintaining relationship with clients and providing business leads, client interaction, team building, follow up with clients.
- Identify potential clients; manage existing account/customer relationships.
- Understanding the requirements of the clients & positioning an appropriate Solution
- Should be able to travel on demand as per the Company Policy.
- Liaisoning with Colleges / institutes for upliftment of biosciences
Desired Candidate Profile
Education:(UG - Any Graduate - Any Specialization, B.Com, B.B.A, B.Pharma, B.Sc,
B.Tech
/B.E.) AND (PG - MBA/PGDM - Advertising/Mass Communication, International Business, Marketing, Other Management,
M.Tech
- Bio-Chemistry/Bio-Technology, Biomedical,
M.Sc
- Bio-Chemistry)
- A minimum of 0 - 3 years of marketing experience
- Good organizational skills and the ability to understand detailed information.
- Basic IT and numeric skills.
- Good interpersonal skills to form effective working relationships with people at all levels.
- A proven track record of 'making a difference'.
- Creative, resourceful, detail-oriented, highly organized.
- Excellent verbal and written communication skills.
- Good Presentation skills.
- Time Management Skills.
- The potential to handle a leadership role.
- Candidate should have pleasing personality with excellent communication skills (Verbal & Written).
- Only candidates who can relocate to bangalore may apply
Executive Name:Sylvia Fernandes
Contact Company: Biotecnika
Address: #2628, 4th Floor 27th Main, Sector 1 HSR Layout, Landmark - CPWD Quarters BANGALORE,Karnataka,India 560102
Apply to Email Address :
jobs@biotecnika.org
Telephone: 80-91-65705331
Reference Id: MAR-10-BDE
March 07, 2012
Drug Company Coupons Are Illegal Bribes Used to Dupe Consumers, Lawsuit Alleges
Three health plans in Community Catalyst's Prescription Access Litigation coalition today filed class action lawsuits in four federal courts against eight major drug companies
BOSTON, MA - Three health plans in Community Catalyst's Prescription Access Litigation coalition today filed class action lawsuits in four federal courts against major drug manufacturers for illegally subsidizing co-payments for expensive brand-name prescription drugs such as Lipitor and Nexium through the promotion of co-pay coupons.
The lawsuit alleges that the payments by eight drug makers -- Abbott, Amgen, AstraZeneca, Bristol-Meyers-Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer -- are illegal under a federal statute that prohibits commercial bribery because the undisclosed payments to patients and pharmacies are made through a ‘shadow claims system' designed to keep information about the presence or amount of these payments from health plans.
Community Catalyst, a national consumer advocacy organization, warns that while prescription drug coupons appear to save consumers money by reducing or eliminating co-payments, in reality they dramatically increase the cost of health care by driving up health insurance premiums and potentially causing consumers to hit benefit caps or lose coverage altogether.
"Pharmaceutical corporations are duping consumers with misleading coupons that are more about increasing corporate profits than actually reducing the cost of drugs for consumers" said Wells Wilkinson, director of the Prescription Access Litigation project at Community Catalyst. "If not stopped, the use of these deceptive coupons will increase costs for consumers' health plans by billions of dollars, contributing to higher premiums and the increasing loss of coverage and benefits for Americans."
A recent report by the Pharmacy Benefit Manager trade association (PCMA) estimates drug coupons will increase drug costs by $32 billion nationwide by 2021. Federal government health plans like Medicare consider these coupons kickbacks and have banned them; they are also banned in Massachusetts under an anti-kickback law.
The lawsuits were filed in New York, Chicago, Philadelphia and Newark by the AFSCME District Council 37 Health & Security Plan Trust, Sergeants Benevolent Association, the New England Carpenters, and the Plumbers and Pipefitters Local 572 Health and Welfare Fund. These health plans provide drug benefits for civilian and uniformed municipals workers, retirees and their dependents throughout the City of New York, plumbers from Florida to Ohio, and carpenters throughout New England. All of these health plans are struggling to keep up with continually rising drug costs.
"Our members are harmed by these unlawful practices by drug companies because coupons offering discounts off of brand drugs don't save consumers money in the long run." says Lillian Roberts, Executive Director of AFSCME, District Council 37, a plaintiff in the lawsuit.
"By combining direct-to-consumer marketing and supermarket ‘coupon clipping,' pharmaceutical companies are steering consumers to higher priced drugs in the pursuit of greater profits" said Edward Mullins, President of the Sergeants Benevolent Association, also a plaintiff in the lawsuit.
Under most health plans, consumers pay a larger co-payment for expensive brand-name drugs. By subsidizing all or the majority of a consumer's co-payment, drug companies promote the sale of these expensive products over less expensive, equally effective medications. This drives up the cost of care for health plans, employers and, ultimately, consumers. In addition, consumers who stay on expensive brand-name drugs run the risk of reaching their coverage caps sooner, forcing them to either pay out of pocket or forgo important care when they need it.
"Drug company coupons are not coupons. They are high-interest loans. We save money now, but we pay the loan sharks later," said Dr. William Jordan, a practicing physician in New York City serving low-income patients.
In 2009, half of the 109 best-selling U.S. brand-name drugs were promoted by coupons, and the number of coupon subsidy programs has skyrocketed since then, from 86 in July 2009 to 362 in November 2011. Coupons are aggressively marketed to consumers by TV, radio, Internet ads, and through physicians and pharmacists. And consumers are using them up, unaware of the negative impact on their premiums. In 2010 alone, co-pay coupons were used in one-eighth of all brand-name drug purchases, or 100 million prescriptions, according to the PCMA report.
Coupons also threaten anticipated savings from so called "patent cliff drugs," the dozens of brand-name drugs going off-patent between 2010 and 2013 and competing for the first time against generic counterparts.
Aside from cost concerns, consumer advocates and policymakers are also concerned about coupons for safety reasons. For instance, the FDA is currently studying whether drug coupons can mislead consumers concerning the safety and risks of drug products.
###
About Community Catalyst
Community Catalyst is a national non-profit consumer advocacy organization dedicated to quality affordable health care for all. Community Catalyst works in partnership with national, state and local consumer organizations, policymakers, and foundations, providing leadership and support to change the health care system so it serves everyone - especially vulnerable members of society. For more information, visit www.communitycatalyst.org. Read or comment on our blog at http://blog.communitycatalyst.org/. Follow us on Twitter @healthpolicyhub.The 130-member Prescription Access Litigation coalition, a project of Community Catalyst, has played a major role in bringing lawsuits challenging illegal pharmaceutical industry pricing or promotional tactics. One lawsuit resulted in over $360 million in settlements with 29 of the country's largest drug makers.
The government in India has granted the rights to an indigenous pharmaceutical group to manufacture a generic version of the cancer treatment drug Nexavar.
For the first time, an Indian drugs firm has been approved to produce a medication under licence when the original's still patent-covered.
As a result of the agreement, the firm - Natco Pharma - is obliged to forward six per cent in royalties back to Bayer, which presently markets Nexavar alongside Onyx Pharmaceuticals.
Bayer, meanwhile - according to reports - isn't best pleased with the Indian government's move. "We are disappointed about this decision", company representative Sabrina Cusimano stated in comments made to the Associated Press. "We will see if we can further defend our intellectual property rights in India".
Nexavar Cancer Drug
Nexavar is the market name for sorafenib, an orally-taken medication now approved to treat two types of cancer - advanced hepatocellular carcinoma (liver cancer) and advanced renal cell carcinoma (kidney cancer).
The kidney cancer approval came first, in 2005, when the US FDA declared its satisfaction with the product. It did the same for the drug as a liver cancer treatment two years later and, with clinical trials now in progress, thyroid cancer could be the next condition added to this approved treatment list.
Controversially, the drug's not available as a
UK liver cancer treatment, after being rejected - on grounds of cost - by the National Institute for Health and Clinical Excellence in November 2009.
Natco Generic Nexavar Approval
The Natco generic Nexavar approval decision will see the production of drug copies priced at the equivalent of £112 for a box of 120: less than £1.00 each. This is dramatically cheaper than the original drug, with the same quantity presently priced at over 30 times that cost.
The Indian pharmaceutical firm believes that the drug's availability is key to the treatment of close to 9,000 cancer patients in India.
"This is a victory for Indian patients and for India's generic manufacturers, which are under attack", Natco Pharma's General Manager, Madineedi Adinarayana, stated according to the BBC, adding: "many more such cases will follow."
MUMBAI: In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer's patented anti-cancer drug, Nexavar, bringing down its price by 97%.
In the first-ever case of compulsory licencing approval, the Indian Patent Office on Monday cleared the application of Hyderabad's
Natco Pharma to sell generic drug Nexavar, used for renal and liver cancer, at Rs 8,880 (around $175) for a 120-capsule pack for a month's therapy.
Bayer offers it for over Rs 2.8 lakh (roughly $5,500) per 120 capsule. The order provides hope for patients who cannot afford these drugs.
The approval paves the way for the launch of Natco's drug in the market, a company official told TOI, adding that it will pay a 6% royalty on net sales every quarter to Bayer. The licence will be valid till such time the drug's patent is valid, i.e. 2020. As per the CL (compulsory licence) order, Natco is also committed to donating free supplies of the medicines to 600 patients each year.
Bayer said it was "disappointed" and would "evaluate options to defend intellectual property rights" in the country. In July 2011, Natco had applied for the CL in the Mumbai patent office to make Sorafenib Tosylate for which Bayer has a patent in the country since 2008.
Arrow Generics UK has launched generic versions of AstraZeneca’s Zomig (Zolmitriptan) and Zomig Rapimelt (Zolmitriptan Orodispersible) in the UK and France.
Arrow, part of the Watson Group, released the generics after the patent expired for the two treatments indicated for patients with migraine headache with or without aura.
Last year, the two treatments had sales in the UK and France of around $107 million in the two markets, according to IMS Health data.
The two generics are also set to be launched in the Nordic region later this month on the date of expiry.
Joining Zolmitriptan and Zolmitriptan Orodispersible, Arrow has also launched a generic alternative of GSK’s Naramig (Naratriptan) – indicated for the same condition.
Symposium
Foster City, California, US
Johnson & Johnson (JNJ) faces a U.S. government demand to raise its offer by $800 million from an initial proposal to settle a federal civil investigation into marketing of the antipsychotic Risperdal, according to three people familiar with the matter.
The Justice Department is demanding that J&J pay about $1.8 billion to resolve the civil claims by the U.S. and some states, the people said. The company raised its offer to settle the civil investigation to $1.3 billion by March 8, and negotiations on a final amount are continuing, one person said.
US Free Classifieds
Most Popular Online Classifieds in USA. No Sign up, No Email Required to Post.
Canada Free Ads
Free Online Classifieds in Canada.
UK Free Ads
United Kingdom Free Ads Website.
100% Free Ad Posting.Are mosquitoes driving you crazy in the evening? Here is a chance to drive those irritating blood sucking creatures that prevents you from going out for a walk in the evening, leaving your skin with rashes and itchiness after a needle like bite! The Skin Armour Deep Woods Outdoor Soap from Facedoctor has now emerged for your rescue. It can be easily applied and is effective, long lasting & safe for people of all ages. Made of sea buckthorn oil, it gives your skin care too. You need not be afraid of mosquitoes from now on.
Our products are available at Wal Mart, Lawtons Drugs, Ultra food & drug, Pharmasave, Sobeys, Rexall's stores and other fine pharmacies. Or Call us Toll Free 1-866-595-6497
View our products at http://tinyurl.com/2vf5w9s
US Free Classifieds
Most Popular Online Classifieds in USA. No Sign up, No Email Required to Post.
Canada Free Ads
Free Online Classifieds in Canada.
UK Free Ads
United Kingdom Free Ads Website.
100% Free Ad Posting.Vitamin A Capsules 25000 IU
Vitamin A and vitamin A-derived medications play a prominent role in human health and disease. Vitamin A is a fat-soluble vitamin with
four major functions in the body: It helps cells reproduce normally,a process called differentiation (cells that have not properly
differentiated are more likely to undergo pre-cancerous changes). It is required for vision; vitamin A maintains healthy cells in
various structures of the eye and is required for the transduction of light into nerve signals in the retina. It is required for normal
growth and development of the embryo and fetus, influencing genes that determine the sequential development of organs in embryonic
development.
Hypromellose (derived from cellulose) capsule. May contain one or more of the following hypoallergenic ingredients to fill space -
Magnesium Citrate, Leucine, Silicon Dioxide.
Vitamin A Capsules 50000 IU
Vitamin A, also called retinol, helps your eyes adjust to light changes when you come in from outside and also helps keep your eyes,
skin and mucous membranes moist. Vitamin A mostly comes from animal foods, but some plant-based foods supply beta-carotene, which your
body then converts into Vitamin A. It also has antioxidant properties that neutralize free radicals in the body that cause tissue and
cellular damage. Vitamin A helps to fight cancer by inhibiting the production of DNA in cancerous cells. It slows down tumor growth in
established cancers and may keep leukemia cells from dividing.
Technical specifications
These are the manufacturing specifications for the vitamin A, including capsule specifications, capsule contents, shelf life, bottling,
and certification requirements.
Capsule Specifications
* Color: Opaque yellow, PMS 114c is recommended as a reference pantone color.
* Gelatin: Must be without BSE infectivity: Reference is made to the Resolution AP/CSP(99)4, AP/CSP(99)T, to EMEA/410/01 ? rev. 1.
* Size: Length: 0.200" +/- 15% width: 0.940 +/- 15%
* Weight: Must conform to manufacturers product specifications
* Hardness: At time of manufacturing, after the drying process, Soft Gelatin Capsules should have a gelatin shell hardness not less
than 6 Newtons, as measured with a Bareiss Hardness Tester, or equivalent.
WWW.BUYMULTIVITAMINMEDICINE.COM is owned by Vipro LIfescience, a leading pharmaceutical company dealing with wide range of generic and
herbal medicine; helping in the field of online medications sales for more than 7 years. Our main aim is to offer our customers highest
quality medications at the most competitive prices. The products offered through this site are mainly vitamin products.
Website: http://www.buymultivitaminmedicine.com/
No comments:
Post a Comment